You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 26, 2024

Maia Pharms Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for MAIA PHARMS INC, and what generic alternatives to MAIA PHARMS INC drugs are available?

MAIA PHARMS INC has nine approved drugs.

There are seven US patents protecting MAIA PHARMS INC drugs.

There are four patent family members on MAIA PHARMS INC drugs in three countries and seventy-two supplementary protection certificates in nine countries.

Summary for Maia Pharms Inc
International Patents:4
US Patents:7
Tradenames:6
Ingredients:6
NDAs:9

Drugs and US Patents for Maia Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Maia Pharms Inc SINCALIDE sincalide POWDER;INTRAVENOUS 210850-001 Nov 22, 2022 RX Yes Yes 11,318,100 ⤷  Sign Up Y ⤷  Sign Up
Maia Pharms Inc ANGIOMAX RTU bivalirudin SOLUTION;INTRAVENOUS 211215-001 Jul 25, 2019 RX Yes Yes 11,903,993 ⤷  Sign Up ⤷  Sign Up
Maia Pharms Inc BORTEZOMIB bortezomib SOLUTION;INTRAVENOUS 215331-002 Jul 27, 2022 DISCN Yes No 11,752,164 ⤷  Sign Up ⤷  Sign Up
Maia Pharms Inc SINCALIDE sincalide POWDER;INTRAVENOUS 210850-001 Nov 22, 2022 RX Yes Yes 11,737,983 ⤷  Sign Up Y ⤷  Sign Up
Maia Pharms Inc SODIUM PHENYLACETATE AND SODIUM BENZOATE sodium benzoate; sodium phenylacetate SOLUTION;INTRAVENOUS 208521-001 May 8, 2017 AP RX No No ⤷  Sign Up ⤷  Sign Up
Maia Pharms Inc BORTEZOMIB bortezomib SOLUTION;INTRAVENOUS 215331-002 Jul 27, 2022 DISCN Yes No 11,679,119 ⤷  Sign Up ⤷  Sign Up
Maia Pharms Inc BORTEZOMIB bortezomib SOLUTION;INTRAVENOUS 215331-001 Jul 27, 2022 DISCN Yes No 11,679,119 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for MAIA PHARMS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Injection 200 mcg/vial ➤ Subscribe 2015-05-01
➤ Subscribe for Injection 100 mcg/vial and 500 mcg/vial ➤ Subscribe 2015-04-14

Supplementary Protection Certificates for Maia Pharms Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1856135 CR 2020 00018 Denmark ⤷  Sign Up PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113
0268956 1999C0030 Belgium ⤷  Sign Up PRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
2666774 LUC00167 Luxembourg ⤷  Sign Up PRODUCT NAME: RELEBACTAM, EVENTUELLEMENT SOUS FORME DE MONOHYDRATE, IMIPENEME ET CILASTATINE, EVENTUELLEMENT SOUS FORME DE SEL DE SODIUM; AUTHORISATION NUMBER AND DATE: EU/1/19/1420 20200217
0186405 SPC/GB00/021 United Kingdom ⤷  Sign Up PRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
1948158 1690020-1 Sweden ⤷  Sign Up PRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123
0579826 SPC/GB02/042 United Kingdom ⤷  Sign Up PRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020422
0489070 22/2004 Austria ⤷  Sign Up PRODUCT NAME: BIVALIRUDIN UND TRIFLUORACETAT DAVON; REGISTRATION NO/DATE: EU/1/04/289/001 20040920
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.